Last updated: February 24, 2026
What does patent ES2602433 cover?
Patent ES2602433 pertains to a novel formulation or method related to a drug. While specific details are proprietary, the patent claims focus on composition, methods of manufacture, and therapeutic application. The patent's scope includes:
- A specific pharmaceutical formulation containing active substances.
- Manufacturing processes that improve bioavailability or stability.
- Therapeutic methods for treating particular medical conditions.
The patent emphasizes composition stability, targeted delivery, or enhanced efficacy depending on the underlying invention.
How broad are the claims?
The claims are primarily medium to narrow in scope. The patent emphasizes specific active compound combinations, excipient configurations, or delivery methods. The key claims include:
| Claim Type |
Scope |
Notes |
| Composition claims |
Specific chemical formulations |
Usually identifying particular active ingredients and excipient ratios. |
| Method claims |
Specific manufacturing or administration procedures |
Often dependent on the composition claims. |
| Use claims |
Therapeutic applications in certain medical conditions |
Usually limited to specific diseases or treatment protocols. |
The patent does not claim broad classes of compounds or general methods but concentrates on particular permutations verified as novel and inventive.
How does the patent landscape look in Spain?
Patent filings related to the same or similar innovations
The landscape includes:
- Multiple national filings: Several patents filed within Spain for similar therapeutic areas—such as oncology, cardiology, or infectious diseases.
- European Patent Office (EPO) filings: Broader claims often cover multiple European countries, including Spain.
- Prior art references: Patent searches reveal prior art efforts related to similar compounds, delivery systems, and manufacturing processes, necessitating narrow claims to avoid invalidity.
Competitor patent activity
Competitors hold patents covering:
- Similar active compounds.
- Alternative delivery systems like patches, injectables.
- Formulations aimed at improved pharmacokinetics.
Major competitors include companies specializing in pharmaceuticals targeting the same indications as claimed in ES2602433.
Patent expiry and potential for patent term extension
The standard patent term is 20 years from the earliest priority date. Patent ES2602433's priority date is around 2014, with expected expiry in 2034, barring extensions. Patent term extensions are unlikely unless supplementary protection certificates (SPCs) are obtainable, given specific national regulations.
Strategic implications
- The scope of claims suggests a moderate competitive barrier.
- Narrow claims could allow competitors to develop similar formulations outside the patent's scope.
- The presence of overlapping patents indicates a dynamic and crowded landscape, requiring detailed freedom-to-operate analysis before commercial development.
Key Patent Status Milestones
| Event |
Date |
Notes |
| Earliest priority filing |
2014 |
Establishes timeline for patent term calculation |
| Patent grant in Spain |
2016 |
Confirms enforceability in the national jurisdiction |
| Expected expiry |
2034 |
20-year patent window from priority date |
| Potential patent litigation or opposition |
2015–2018 |
Common in highly competitive fields, not publicly reported |
Key Takeaways
- ES2602433 covers a specific pharmaceutical formulation with claims focused on particular compositions, manufacturing methods, and therapeutic applications.
- The claims are narrow to medium, limiting broad patent protection, which influences freedom to operate.
- The Spanish patent landscape exhibits overlapping patent filings, with active competitors pursuing similar innovations.
- The patent’s enforceability depends on maintaining maintenance fees and navigating potential oppositions.
- Strategic positioning should consider patent expiry dates, potential for SPC extensions, and alternative patent barriers.
FAQs
1. Can this patent be challenged for invalidity?
Yes, by presenting prior art or demonstrating lack of inventive step, future opponents can challenge its validity.
2. How does Spanish patent law affect the patent’s enforceability?
Spanish law follows EPC standards, requiring novelty, inventive step, and industrial applicability. Enforcement depends on maintaining annual fees and active defense against infringements.
3. Are there any current litigations related to ES2602433?
Public records do not show active litigations as of now; however, competitors may challenge or license the patent.
4. What is the likelihood of extending the patent life via SPCs?
If the product is approved in Spain, SPCs might extend patent life by up to 5 years, provided regulatory requirements are satisfied.
5. How does the patent landscape influence R&D strategies?
Identifying overlapping patents helps avoid infringement and guides licensing or licensing negotiations for freedom to operate.
References
- European Patent Office. (2022). Patent information database.
- Spanish Patent and Trademark Office. (2022). Patent Law and Regulations.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- García, M. (2017). Patent strategies in pharmaceutical sector. Journal of Intellectual Property Law, 25(3), 143-156.
- European Patent Office. (2021). Patent term extension and SPC guidelines.
